Infectious Diseases News and Research

RSS

Salk researchers move one step closer to making cures for genetic diseases a reality

Healthy brain, muscle, eye and heart cells would improve the lives of tens of thousands of people around the world with debilitating mitochondrial diseases. Now, researchers at the Salk Institute have gotten one step closer to making such cures a reality: they've turned cells from patients into healthy, mutation-free stem cells that can then become any cell type.

16 Jul 2015

UK investment lacking for pneumonia research

UK investment in pneumonia research is lacking when compared to spending on influenza and tuberculosis, according to a new study by the University of Southampton and University College London.

15 Jul 2015

New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful.

15 Jul 2015

IU researcher plays role in recent FDA approval of Neupogen drug to treat people exposed to radiation

An Indiana University Melvin and Bren Simon Cancer Center researcher played a role in the recent Food and Drug Administration approval of a drug to treat people exposed to potentially lethal doses of radiation.

15 Jul 2015

Salk professor receives Allen Distinguished Investigator award to uncover biology of Alzheimer's disease

The Salk Institute today announced that Rusty Gage, Salk professor in the Laboratory of Genetics, has been selected as one of five recipients of the Paul G. Allen Family Foundation's Allen Distinguished Investigator (ADI) program and will be awarded $1.5 million to conduct his research. These researchers have projects aimed at uncovering the elusive biological foundations of Alzheimer's disease.

15 Jul 2015

VUMC becomes Human Vaccines Project's first scientific hub

Vanderbilt University Medical Center, the Human Vaccines Project and the International AIDS Vaccine Initiative are pleased to announce that VUMC has become the Project's first scientific hub.

14 Jul 2015

Researchers discover role of RORC mutations in patients with candidiasis and mycobacteriosis

The discovery of bi-allelic mutations in RORC in patients with candidiasis and mycobacteriosis revealed the pivotal role of RORC in mucocutaneous immunity to Candida and in systemic immunity to Mycobacterium in humans.

13 Jul 2015

Acceleration of cell cycle transition kinetic can make human blood stem cells more powerful

For the first time, the research group of Prof. Claudia Waskow at the Carl Gustav Carus Faculty of Medicine at Dresden Technical University is now describing a new mechanism in which the length of the G1 phase of the cell cycle has a dramatic impact on the fitness of human blood stem cells.

13 Jul 2015

Barbara Murray recognized by Association of Rice Alumni for contributions to infectious disease research

Barbara Murray, M.D., director of the Division of Infectious Diseases at The University of Texas Health Science Center at Houston Medical School, was recognized by the Association of Rice Alumni at its Laureates Dinner May 16.

12 Jul 2015

Microbiota blocks the immune cells responsible for triggering allergies

The human body is inhabited by billions of symbiotic bacteria, carrying a diversity that is unique to each individual. The microbiota is involved in many mechanisms, including digestion, vitamin synthesis and host defense.

12 Jul 2015

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the National Institutes of Health to develop a non-antibiotic treatment for Clostridium difficile (C. diff) infections.

10 Jul 2015

Starting anti-HIV treatment early improves survival among patients with newly diagnosed TB

Starting anti-HIV treatment within two weeks of the diagnosis of tuberculosis, or TB, improved survival among patients with both infections who had very low immune-cell counts, according to an analysis by researchers at the University of Pittsburgh Graduate School of Health.

10 Jul 2015

Trial results show routine oral cholera vaccination programme protects people living in endemic regions

An oral cholera vaccine given as part of routine health services is safe and protects against severe cholera in children and adults in urban Bangladesh where the disease is endemic, according to the first real-life trial of this vaccine published in The Lancet.

10 Jul 2015

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.

9 Jul 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

Study analyzes attitudes and practices of general physicians in different vaccination scenarios

At population level, vaccines contribute to reducing mortality associated with infectious diseases such as measles, diphtheria, tetanus, hepatitis B or bacterial meningitis.

9 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

Southern Research receives $22 million to support HIV cure initiative

Southern Research has been awarded a seven-year contract of up to $22 million to support research that could contribute to the cure of HIV disease. Under this contract, Southern Research will develop and standardize assays that quantitate latent reservoirs of HIV.

7 Jul 2015

CPhA urges federal government to enhance HPV vaccination programs for young Canadians

The Canadian Pharmacists Association (CPhA) urges the federal government to enhance its national immunization strategy to ensure that all Canadians have the opportunity to protect themselves against the common strains of HPV (human papillomavirus) through immunization.

7 Jul 2015

Study sheds light on how dengue virus adapts, causes outbreaks as it travels

A researcher from The University of Texas Medical Branch at Galveston is an integral member of a collaborative group that is the first to explain the mechanisms that the Dengue virus has developed to optimize its ability to cause outbreaks as it travels across the globe to new places and revisits old ones.

7 Jul 2015

Infectious Diseases News and Research

Salk researchers move one step closer to making cures for genetic diseases a reality

UK investment lacking for pneumonia research

New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

IU researcher plays role in recent FDA approval of Neupogen drug to treat people exposed to radiation

Salk professor receives Allen Distinguished Investigator award to uncover biology of Alzheimer's disease

VUMC becomes Human Vaccines Project's first scientific hub

Researchers discover role of RORC mutations in patients with candidiasis and mycobacteriosis

Acceleration of cell cycle transition kinetic can make human blood stem cells more powerful

Barbara Murray recognized by Association of Rice Alumni for contributions to infectious disease research

Microbiota blocks the immune cells responsible for triggering allergies

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Starting anti-HIV treatment early improves survival among patients with newly diagnosed TB

Trial results show routine oral cholera vaccination programme protects people living in endemic regions

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Study analyzes attitudes and practices of general physicians in different vaccination scenarios

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Southern Research receives $22 million to support HIV cure initiative

CPhA urges federal government to enhance HPV vaccination programs for young Canadians

Study sheds light on how dengue virus adapts, causes outbreaks as it travels

NGS for Infectious Disease Surveillance eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News